The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal.

ABSTRACT:

Background

Erenumab, a fully human monoclonal antibody directed against the calcitonin gene-related peptide receptor, was approved for the prevention of episodic (EM) or chronic migraine (CM) at the monthly dose of 70 mg or 140 mg. We reviewed the available literature to understand if patients with prior preventive treatment failures benefit more from the 140 mg dose than the 70 mg.

Main body

We searched papers indexed in PubMed and conference abstracts published in the last 2 years which assessed the safety and efficacy of erenumab in patients with prior preventive treatment failures. We reviewed the results of 3 randomized controlled trials and their subgroup analyses and open-label extensions. The 140 mg monthly dose of erenumab had a numerical advantage over the 70 mg mo

SUBMITTER: Ornello R 

PROVIDER: S-EPMC6822439 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature